Exhibit 99.2

Purple Biotech Ltd.

Condensed Consolidated

Unaudited Interim Financial Statements

As of June 30, 2024

Contents

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

The accompanying notes are integral part of these condensed consolidated interim financial statements.

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Note 1 - General

The Company was incorporated in Israel as a private company in August 1968, and has been listed for trading on the Tel Aviv Stock Exchange since September 1978. In October 2012, the Company disposed all its previous operations, and in July 2013, the Company acquired shares of Kitov Pharma Ltd. from its shareholders, in exchange for the Company’s shares. In December 2020 the Company changed its name from Kitov Pharma Ltd. to Purple Biotech Ltd.

The Company’s address is 4 Oppenheimer St., Science Park, Rehovot 7670104 Israel.

The Company together with its subsidiaries TyrNovo LTD, FameWave LTD, Purple Biotech GmbH and Immunorizon LTD are referred to, in these consolidated financial statements, as “the Group”.

Note 2 - Basis of Preparation

These condensed consolidated interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting and do not include all of the information required for full annual financial statements. They should be read in conjunction with the financial statements as at and for the year ended December 31, 2023 (hereinafter - “the Annual Financial Statements”). However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group’s financial position and performance since the last Annual Financial Statements.

These condensed consolidated interim financial statements were approved for issue by the Group’s Board of Directors on August 15, 2024.

The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

The significant judgments made by management in applying the Group’s accounting policies and the principal assumptions used in the estimation of uncertainty were the same as those that applied to the Annual Financial Statements.

Note 3 - Material Accounting Policies

The accounting policies applied by the Group in these condensed consolidated interim financial statements are the same as those applied by the Group in its Annual Financial Statements except as described below.

Initial application of new standards, amendments to standards, and interpretations:

Amendment to IAS 1, Presentation of Financial Statements: Classification of liabilities as current or non-current

The amendment replaces the specific classification requirement of certain liabilities as current or non-current. According to the amendment, a liability will be classified as non-current when the entity has a right to defer payment for a period of at least 12 months after the reporting period, which is "substantive" (Substance) and which exists at the end of the reporting period. The amendment clarifies that the conversion right of a liability will affect the classification of the instrument as a whole as current or non-current unless the conversion component is equity. The amendment is affective retrospectively for reporting periods beginning on or after January 1, 2024.

As a result of implementing the amendment, the company changed its policy regarding the classification of warrants classified as a liability. Prior to the implementation of the amendment, when classifying the warrants as current or non-current, the conversion options of the counterparty were not considered. Following the implementation of the amendment, since the warrants include a conversion component, the company takes into account the possible date at which the warrants can be converted, when classifying the warrants as current or non-current. Since the conversion option can be exercised within 12 months after the reporting period, the company retrospectively classified the warrants as a current liability.

Accounting standards issued not yet adopted:

IFRS 18, Presentation and Disclosure in Financial Statements.

This standard replaces IAS 1, Presentation of Financial Statements. The purpose of the standard is to provide improved structure and content for financial statements, particularly in the income statement. The standard includes new disclosure and presentation requirements as well as requirements brought from IAS 1, Presentation of Financial Statements with minor wording changes. As part of the new disclosure requirements, companies will be required to present two intermediate summaries in the profit or loss statement: operating profit and profit before finance and tax. In addition, for most companies, the results in the profit or loss statement will be classified into three categories: operating profit, investment profit, and financing profit. In addition to changes in the structure of the profit and loss statements, the standard also includes a requirement to provide a separate disclosure in the financial statements regarding the use of performance measures defined by management (non-GAAP measures). Also, as part of the amendment, specific guidance was added for the aggregation and disaggregation of items in the financial statements and notes. The standard will encourage companies to avoid classifying items as 'other' (e.g., other expenses), and such classification will trigger additional disclosure requirements. The standard is effective retrospectively for annual periods beginning on or after January 1, 2027, with early application permitted. The group is examining the implications of the amendment on the financial statements.

Amendments to IFRS 9 and IFRS 7 (Financial Instruments)

In May 2024, the IASB issued amendments to IFRS 9 (Financial instruments) and IFRS 7 (Financial instruments – Disclosures). The amendments provide clarifications for the timing of recognition and derecognition of financial instruments, adding an exception regarding the write off date of financial liabilities that are eliminated in electronic transfers of cash. The amendments also relate to the classification of financial assets and include updated guidance on how to assess whether contractual cash flows of a financial asset are solely payments of principal and interest (SPPI) when the contractual terms and interest of the asset include conditional features, adding examples such as index-linking to ESG. The amendments clarify when financial instruments are contractually linked and when they constitute non-recourse financial assets for the purpose of determining whether they include only payments of principal and interest (SPPI). The amendments also add certain disclosure requirements for financial instruments with conditional features and for equity instruments measured at fair value through other comprehensive income. The amendments are effective for annual periods beginning on or after January 1, 2026, with early adoption permitted. The Group is currently assessing the potential effect of these amendments.

Note 4 - Capital and reserves

During the reported periods, the following shares were issued:

Note 5 - Financial Instruments

Financial instruments measured at fair value 

Fair value hierarchy of financial instruments measured at fair value:

Details regarding fair value measurement at Level 3:

Note 6 - Share-based payments

In the reporting period, no share-based payments were granted.

During the three and six-month period ended June 30, 2024 the Company recorded gross expenses of USD 238 thousand and USD 535 thousand, net of expenses forfeited for employees who left amounting to USD 20 thousand and USD 51 thousand, respectively.

Of these amounts, USD 220 thousand and USD 485 thousand are attributed to key management personnel, respectively. (For the three and six-month period ended June 30, 2023 the Company recorded an expense of USD 493 thousand and USD 1,245 thousand of which USD 417 thousand and USD 1,095 thousand are to key management personnel, respectively).

Note 7 - Commitments and contingent liability

2017 Motions to Approve a Class Action in Israel

Following proceedings described in Note 13B(3) to the annual Financial statements of 2023, on June 19, 2024, the Tel Aviv District Court (Economic Division) dismissed the previously disclosed lawsuit and motion to approve the lawsuit as a class action lawsuit which was filed against the Company, its executive directors and certain of its present and former directors in February 2017 (the “2017 Motion”). As previously disclosed, in the 2017 Motion the plaintiffs alleged, among other things, that the Company included misleading information in its public filings related to its former lead drug candidate, Consensi, which caused the class for which the plaintiffs were seeking recognition an aggregate loss of approximately NIS 29 million (approximately $7.8 million). The Court has issued its final decision in the 2017 Motion, whereby it fully dismissed the lawsuit against the defendants as well as the motion to approve the lawsuit as a class action lawsuit. Each party will bear its own court expenses.

Note 8 - Subsequent Events

In consideration for the exercise of the existing warrants, the Company issued new unregistered Series A-1 warrants to purchase up to an aggregate of 4,979,383 ADSs and new unregistered Series A-2 warrants to purchase up to an aggregate of 6,287,635 ADSs. The new warrants are immediately exercisable at an exercise price of $0.40 per ADS. The Series A-1 warrants have a term of five years from the issuance date and the Series A-2 warrants have a term of twenty-four months from the issuance date.

In addition, the Company issued to the placement agent (or its designees) unregistered compensation warrants to purchase up to 394,346 ADSs at an exercise price of USD 0.45 per ADS. The unregistered placement agent warrants are immediately exercisable and have a term of five years from the date of July 2, 2024.